NCT06603259
The Galleri® Community Research Program
Enrolling by Invitation
Not specifiedAll AgesObservationalGRAIL, Inc.
~250 participants
Updated 2024-09-19 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quality of data retrieved from participants who have received the Galleri test
Measured over From enrollment to the the end of study (12 month study participation period), data will be retrieved and assessed for this measure.
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Mai Tran, MPA · PRINCIPAL_INVESTIGATOR · GRAIL, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Have received the Galleri test prescribed by a provider per clinical care
Capable of giving signed and legally effective informed consent. Consent provided by a legally authorized representative is not permitted in this protocol.
Have signed HIPAA authorization(s)\* form for their medical records to be released and used for this study.
Exclusion
Patients are excluded from the study if the patient is a GRAIL employee or contractor.
Patients who have received the Galleri test in a GRAIL-sponsored research setting (i.e., clinical trial) are excluded.
What this trial measures
- Quality of data retrieved from participants who have received the Galleri testFrom enrollment to the the end of study (12 month study participation period), data will be retrieved and assessed for this measure.
Data quality is measured by data completeness and accuracy of key cancer outcome data elements retrieved from medical records for confirmed cancer cases of participants who received the Galleri test.